Abstract
Many patients with atopic dermatitis (AD) exhibit itch that is disproportionate to rash. Limited therapies specifically target itch in AD. Difelikefalin (DFK), a selective kappa-opioid receptor agonist, is being developed for chronic pruritic conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
